Etentamig (ABBV-383)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Etentamig (ABBV-383), covering 2026-02-17 to 2026-02-17. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib [Phase 1, Phase 2]